At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 42 enrolled
Drug / intervention
lanreotide (Autogel formulation)drug
Likely dose
lanreotide (Autogel formulation) 120mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II-III, Multicentre, Prospective, Exploratory, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120mg in the Symptomatic Treatment of Patients With Refractory Diarrhea
In Brief
A Phase 3 clinical trial evaluating lanreotide (Autogel formulation) for Diarrhea. Completed, enrolled 42 participants across 11 sites.
Detailed Summary
The purpose of this study, is to assess the effect of lanreotide Autogel 120mg on stool frequency in subjects with refractory diarrhea at day 28 (mean of last 7 days) compared to baseline.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiarrhea
CountriesBelgium
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartJul 2009
Primary CompletionAug 2012
Study CompletionAug 2013
TodayJul 2026
First PostedMay 1, 2009
Enrollment StartJul 1, 2009
Primary CompletionAug 1, 2012
Study CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 17.2 years ago
Interventions
lanreotide (Autogel formulation)drug
Autogel 120mg